Corlentor

Pays: Union européenne

Langue: anglais

Source: EMA (European Medicines Agency)

Achète-le

Ingrédients actifs:

ivabradine hydrochloride

Disponible depuis:

Les Laboratoires Servier

Code ATC:

C01EB17

DCI (Dénomination commune internationale):

ivabradine

Groupe thérapeutique:

CARDIAC THERAPY

Domaine thérapeutique:

Angina Pectoris; Heart Failure

indications thérapeutiques:

Symptomatic treatment of chronic stable angina pectorisIvabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. Ivabradine is indicated:in adults unable to tolerate or with a contraindication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.Treatment of chronic heart failureIvabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

Descriptif du produit:

Revision: 26

Statut de autorisation:

Authorised

Date de l'autorisation:

2005-10-25

Notice patient

                                28
B. PACKAGE LEAFLET
29
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
CORLENTOR 5 MG FILM-COATED TABLETS
CORLENTOR 7.5 MG FILM-COATED TABLETS
ivabradine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Corlentor is and what it is used for
2.
What you need to know before you take Corlentor
3.
How to take Corlentor
4.
Possible side effects
5
How to store Corlentor
6.
Contents of the pack and other information
1.
WHAT CORLENTOR IS AND WHAT IT IS USED FOR
Corlentor (ivabradine) is a heart medicine used to treat:
-
Symptomatic stable angina pectoris (which causes chest pain) in adult
patients whose heart rate is
over or equal to 70 beats per minute.
It is used in adult patients who do not tolerate or cannot take
heart medicines called beta-blockers. It is also used in combination
with beta-blockers in adult
patients whose condition is not fully controlled with a beta-blocker.
-
Chronic heart failure in adult patients whose heart rate is over or
equal to 75 beats per minute. It
is used in combination with standard therapy, including beta-blocker
therapy or when beta-
blockers are contraindicated or not tolerated.
About stable angina pectoris (usually referred to as “angina”):
Stable angina is a heart disease which happens when the heart does not
receive enough oxygen. The
most common symptom of angina is chest pain or discomfort.
About chronic heart failure :
Chronic heart failure is a heart disease which happens when your heart
cannot pump enough blood to
the rest of your body. The most common s
                                
                                Lire le document complet
                                
                            

Résumé des caractéristiques du produit

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Corlentor 5 mg film-coated tablets
Corlentor 7.5 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Corlentor 5 mg film-coated tablets
Each film-coated tablet contains 5 mg ivabradine (as hydrochloride).
_Excipient with known effect:_
Each film-coated tablet contains 63.91 mg lactose monohydrate.
Corlentor 7.5 mg film-coated tablets
Each film-coated tablet contains 7.5 mg ivabradine (as hydrochloride).
_Excipient with known effect:_
Each film-coated tablet contains 61.215 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Corlentor 5 mg film-coated tablets
Salmon-coloured, oblong, film-coated tablet scored on both sides,
engraved with “5” on one face
and
on the other face.
The tablet can be divided into equal doses.
Corlentor 7.5 mg film-coated tablets
Salmon-coloured, triangular, film-coated tablet engraved with
“7.5” on one face and
on the other
face.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Symptomatic treatment of chronic stable angina pectoris
Ivabradine is indicated for the symptomatic treatment of chronic
stable angina pectoris in coronary
artery disease adults with normal sinus rhythm and heart rate ≥ 70
bpm. Ivabradine is indicated :
-
in adults unable to tolerate or with a contraindication to the use of
beta-blockers
-
or in combination with beta-blockers in patients inadequately
controlled with an optimal beta-
blocker dose.
Treatment of chronic heart failure
3
Ivabradine is indicated in chronic heart failure NYHA II to IV class
with systolic dysfunction, in adult
patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in
combination with standard therapy
including beta-blocker therapy or when beta-blocker therapy is
contraindicated or not tolerated (see
section 5.1).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Symptomatic treatment of chronic stable angina pectoris _
It is recommended that the decision to ini
                                
                                Lire le document complet
                                
                            

Documents dans d'autres langues

Notice patient Notice patient bulgare 12-10-2021
Rapport public d'évaluation Rapport public d'évaluation bulgare 25-02-2019
Notice patient Notice patient espagnol 12-10-2021
Rapport public d'évaluation Rapport public d'évaluation espagnol 25-02-2019
Notice patient Notice patient tchèque 12-10-2021
Rapport public d'évaluation Rapport public d'évaluation tchèque 25-02-2019
Notice patient Notice patient danois 12-10-2021
Rapport public d'évaluation Rapport public d'évaluation danois 25-02-2019
Notice patient Notice patient allemand 12-10-2021
Rapport public d'évaluation Rapport public d'évaluation allemand 25-02-2019
Notice patient Notice patient estonien 12-10-2021
Rapport public d'évaluation Rapport public d'évaluation estonien 25-02-2019
Notice patient Notice patient grec 12-10-2021
Notice patient Notice patient français 12-10-2021
Rapport public d'évaluation Rapport public d'évaluation français 25-02-2019
Notice patient Notice patient italien 12-10-2021
Rapport public d'évaluation Rapport public d'évaluation italien 25-02-2019
Notice patient Notice patient letton 12-10-2021
Rapport public d'évaluation Rapport public d'évaluation letton 25-02-2019
Notice patient Notice patient lituanien 12-10-2021
Rapport public d'évaluation Rapport public d'évaluation lituanien 25-02-2019
Notice patient Notice patient hongrois 12-10-2021
Rapport public d'évaluation Rapport public d'évaluation hongrois 25-02-2019
Notice patient Notice patient maltais 12-10-2021
Rapport public d'évaluation Rapport public d'évaluation maltais 25-02-2019
Notice patient Notice patient néerlandais 12-10-2021
Rapport public d'évaluation Rapport public d'évaluation néerlandais 25-02-2019
Notice patient Notice patient polonais 12-10-2021
Rapport public d'évaluation Rapport public d'évaluation polonais 25-02-2019
Notice patient Notice patient portugais 12-10-2021
Rapport public d'évaluation Rapport public d'évaluation portugais 25-02-2019
Notice patient Notice patient roumain 12-10-2021
Rapport public d'évaluation Rapport public d'évaluation roumain 25-02-2019
Notice patient Notice patient slovaque 12-10-2021
Rapport public d'évaluation Rapport public d'évaluation slovaque 25-02-2019
Notice patient Notice patient slovène 12-10-2021
Rapport public d'évaluation Rapport public d'évaluation slovène 25-02-2019
Notice patient Notice patient finnois 12-10-2021
Rapport public d'évaluation Rapport public d'évaluation finnois 25-02-2019
Notice patient Notice patient suédois 12-10-2021
Rapport public d'évaluation Rapport public d'évaluation suédois 25-02-2019
Notice patient Notice patient norvégien 12-10-2021
Notice patient Notice patient islandais 12-10-2021
Notice patient Notice patient croate 12-10-2021
Rapport public d'évaluation Rapport public d'évaluation croate 25-02-2019

Rechercher des alertes liées à ce produit

Afficher l'historique des documents